ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. 2019

Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
Section of Endocrine Surgery, Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstraße 1, D-55131 Mainz, Germany. Electronic address: julia.staubitz@unimedizin-mainz.de.

Rearrangements of RET are drivers of oncogenesis, traceable in different cancer types as papillary thyroid carcinoma (PTC), non-small cell lung cancer, colorectal or breast cancer. Anchored multiplex PCR based next-generation sequencing (NGS) can detect RET rearrangements involving previously unknown partner genes. A sample of PTC underwent NGS, following detection of RET rearrangement by fluorescence in situ hybridization. Expression analysis of ANKRD26 and RET was performed for the tumor harboring ANKRD26-RET, for corresponding normal thyroid tissue and PTC tumors with representative genetic alterations (BRAFV600E, CCDC6-RET), complemented by a comparative search in the "UniProt" database. NGS analysis resulted in the discovery of the fusion ANKRD26-RET. ANKRD26 mRNA was expressed in all PTC tumors (ANKRD26-RET, BRAFV600E, CCDC6-RET) and in normal thyroid tissue, whereas RET mRNA was detected only in the tumors with RET rearrangement. On protein level, ANKRD26-RET combines the RET tyrosine kinase to ankyrin repeat and coiled-coil domains. ANKRD26-RET is a novel rearrangement of the RET gene, associated with RET expression in thyroid tissue. The result is a fusion of the RET tyrosine kinase to prominent protein-protein interaction motifs. Further studies are required to investigate the influence of different RET rearrangements on metastasis and disease-free survival in PTC.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077273 Thyroid Cancer, Papillary An ADENOCARCINOMA that originates from follicular cells of the THYROID GLAND and accounts for the majority of THYROID CANCER cases. Cells exhibit enlarged, oval, or elongated morphologies with clear, round, nuclei. Fusions of RET, NTRK1, TPM3, and PCM1 genes are associated with this cancer. Familial Nonmedullary Thyroid Cancer,Nonmedullary Thyroid Carcinoma,Papillary Carcinoma Of Thyroid,Papillary Thyroid Carcinoma,Thyroid Carcinoma, Papillary,Cancer, Papillary Thyroid,Cancers, Papillary Thyroid,Carcinoma, Nonmedullary Thyroid,Carcinoma, Papillary Thyroid,Carcinomas, Nonmedullary Thyroid,Carcinomas, Papillary Thyroid,Nonmedullary Thyroid Carcinomas,Papillary Thyroid Cancer,Papillary Thyroid Cancers,Papillary Thyroid Carcinomas,Thyroid Cancers, Papillary,Thyroid Carcinoma, Nonmedullary,Thyroid Carcinomas, Nonmedullary,Thyroid Carcinomas, Papillary
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D050939 Gene Fusion The GENETIC RECOMBINATION of the parts of two or more GENES resulting in a gene with different or additional regulatory regions, or a new chimeric gene product. ONCOGENE FUSION includes an ONCOGENE as at least one of the fusion partners and such gene fusions are often detected in neoplastic cells and are transcribed into ONCOGENE FUSION PROTEINS. ARTIFICIAL GENE FUSION is carried out in vitro by RECOMBINANT DNA technology. Fusion, Gene,Fusions, Gene,Gene Fusions
D051096 Proto-Oncogene Proteins c-ret Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2. c-ret Protein,ret Proto-Oncogene Proteins,Proto-Oncogene Protein Ret,Proto-Oncogene Protein c-ret,Receptor Tyrosine Kinase RET,Proto Oncogene Protein Ret,Proto Oncogene Protein c ret,Proto Oncogene Proteins c ret,Proto-Oncogene Proteins, ret,Ret, Proto-Oncogene Protein,c-ret, Proto-Oncogene Protein,c-ret, Proto-Oncogene Proteins,ret Proto Oncogene Proteins
D059014 High-Throughput Nucleotide Sequencing Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc. High-Throughput Sequencing,Illumina Sequencing,Ion Proton Sequencing,Ion Torrent Sequencing,Next-Generation Sequencing,Deep Sequencing,High-Throughput DNA Sequencing,High-Throughput RNA Sequencing,Massively-Parallel Sequencing,Pyrosequencing,DNA Sequencing, High-Throughput,High Throughput DNA Sequencing,High Throughput Nucleotide Sequencing,High Throughput RNA Sequencing,High Throughput Sequencing,Massively Parallel Sequencing,Next Generation Sequencing,Nucleotide Sequencing, High-Throughput,RNA Sequencing, High-Throughput,Sequencing, Deep,Sequencing, High-Throughput,Sequencing, High-Throughput DNA,Sequencing, High-Throughput Nucleotide,Sequencing, High-Throughput RNA,Sequencing, Illumina,Sequencing, Ion Proton,Sequencing, Ion Torrent,Sequencing, Massively-Parallel,Sequencing, Next-Generation
D036341 Intercellular Signaling Peptides and Proteins Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal. Growth Factor,Growth Factors,Paracrine Peptide Factors,Paracrine Protein Factors,Factor, Growth,Factors, Growth,Peptide Factors, Paracrine

Related Publications

Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
August 2000, Oncogene,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
June 2007, Endocrine-related cancer,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
June 1999, Genes, chromosomes & cancer,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
March 2015, The Journal of clinical endocrinology and metabolism,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
May 2024, European journal of nuclear medicine and molecular imaging,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
October 2023, Gland surgery,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
November 2001, Advances in anatomic pathology,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
July 2015, Cancer,
Julia Isabelle Staubitz, and Thomas Johannes Musholt, and Arno Schad, and Erik Springer, and Hauke Lang, and Krishnaraj Rajalingam, and Wilfried Roth, and Nils Hartmann
March 2021, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!